SCHEMBL724292

SCHEMBL724292

O=S(=O)(c1ccccc1)n1ccnc1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
ALDH3A1 P30838 1/20 0.48
HTR6 P50406 6/20 0.46
CYP2C19 P33261 2/20 0.46
MET P08581 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.46
ALDH1A1 P00352 4/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
LIMK2 P53671 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28219756 0.94 PKM (0.52) PKMALDH3A1HTR6CYP2C19MET
SCHEMBL723626 0.89 MET (0.51) HTR6CYP2C19METALDH1A1SMN1; SMN2
SCHEMBL770698 0.86 L3MBTL1 (0.50) ALDH3A1HTR6CYP2C19METRAPGEF4
SCHEMBL18040300 0.85 ALDH3A1 (0.48) PKMALDH3A1HTR6CYP2C19MET
SCHEMBL15902658 0.85 MEN1 (0.47) PKMHTR6CYP2C19METALDH1A1
SCHEMBL28219316 0.84 MET (0.55) HTR6METALDH1A1MEN1KMT2A
SCHEMBL18040298 0.81 HTR6 (0.46) HTR6CYP2C19MET
SCHEMBL18040302 0.81 MEN1 (0.51) HTR6RAPGEF4ALDH1A1RAB9ASMN1; SMN2
SCHEMBL724342 0.80 KMT2A (0.51) PKMHTR6METALDH1A1RAB9A
SCHEMBL28303263 0.80 L3MBTL1 (0.54) ALDH3A1CYP2C19METRAPGEF4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
CN-105163584-B Compounds for the treatment of cancer 田纳西大学研究基金会 2019-06-04 CN disclosed
CN-109568312-A Compound for treating cancer 田纳西大学研究基金会 2019-04-05 CN disclosed
EP-2608671-B1 COMPOUNDS FOR TREATMENT OF CANCER GTX INC (US) 2018-12-12 EP disclosed
CN-103442566-A Compounds for treatment of cancer GTX INC 2013-12-11 CN disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 EP disclosed
CN-102883607-A Compounds for the treatment of cancer GTX INC (US) 2013-01-16 CN disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PKM 974/4885ALDH3A1 1056/4885HTR6 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.